Jasper Therapeutics, Inc. JSPR
Nov 4, 2026, 1:14 PM EST
- YTD
- -74.09%
- 1 year
- -73.81%
- Market cap
- 15.78M
- EPS (ttm)
- -1.04
- Shares out
- 15.00M
- Forward P/E
- -4.89
- YTD return
- -74.09%
- 1-year return
- -73.81%
- Volume
- 590.27K
- Avg volume
- 491.07K
- Open
- 0.4656
- Previous close
- 0.48
- Day's range
- 0.44 – 0.4962
- 52-week range
- 0.315 – 2.42
- Beta
- 2.20
- Analysts
- Strong Buy
- Price target
- 68.78 (+14407.0%)
- Earnings date
- Aug 13, 2024
2Y -21.5554 (-97.85%)
Key statistics
- Enterprise value
- 233.15M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.97
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -36.91M
- Total cash
- 92.50M
- Total debt
- 2.07M
- Return on equity
- -71.46%
- Short % of float
- 13.88%
- 50-day average
- 21.46
- 200-day average
- 21.97
Analyst view
Consensus: strong buy
- Target (low)
- 43.00
- Target (mean)
- 68.78
- Target (high)
- 90.00
- Strong buy4
- Buy7
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -1.22.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -1.09 | -1.24 | -0.15 | -13.76% |
| Aug 13, 2024 | Jun 1, 2024 | -1.09 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | -1.09 | -0.97 | +0.12 | +11.01% |
| May 14, 2024 | Mar 1, 2024 | -1.26 | -1.03 | +0.23 | +18.25% |
| May 14, 2024 | Mar 1, 2024 | -1.26 | — | — | — |
| Mar 4, 2024 | Dec 1, 2023 | -1.65 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | RBC Capital | reit | Outperform | Outperform |
| Dec 6, 2024 | BMO Capital | init | — | Outperform |
| Oct 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 15, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Oct 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 27, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
About Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- jaspertherapeutics.com
News
Jasper Therapeutics Announces 1-for-30 Reverse Stock Split 
Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy 
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants 
Jasper Therapeutics Appoints Jeet Mahal As Interim Principal Financial Officer Effective October 9, 2026; Herb Cross Resigns As CFO Effective October 9, 2026 
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments 
Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
Why Dell Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Tuesday's Intraday Session 
Jasper Therapeutics Q2 EPS $(0.10) Beats $(0.26) Estimate
Your note
Sign in to keep a note on JSPR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARLYLE GROUP, INC. | Unknown | Purchase | Feb 7, 2024 | 0 |
| EMSTER KURT VON | Director | Sale | Apr 12, 2023 | 21,175 |
| FRENCH ANNA LOUISE | Director | Sale | Apr 13, 2023 | 23,750 |
| LIS WILLIAM DAVID | Director | Sale | Oct 12, 2023 | 53,521 |
| MAHAL JEETINDER SINGH | Chief Operating Officer | Conversion of Exercise of derivative security | Dec 11, 2024 | 25,009 |
| QIMING U.S. HEALTHCARE FUND II, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 26, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Velan Capital Investment Management LP | 9.56% | 1,433,828 | 31.72M | Sep 29, 2024 |
| Soleus Capital Management, L.P. | 8.96% | 1,343,665 | 29.72M | Sep 29, 2024 |
| Carlyle Group Inc. | 7.11% | 1,066,189 | 23.58M | Sep 29, 2024 |
| Qiming U.s. Ventures Management, Llc | 6.19% | 928,964 | 20.55M | Sep 29, 2024 |
| Blackrock Inc. | 5.33% | 800,028 | 17.70M | Sep 29, 2024 |
| Vanguard Group Inc | 4.63% | 694,425 | 15.36M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.67% | 401,219 | 8.87M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.98% | 296,675 | 6.56M | Oct 30, 2024 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 1.58% | 236,841 | 5.24M | Jul 30, 2024 |
| Vanguard Extended Market Index Fund | 1.26% | 188,656 | 4.17M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.77% | 115,362 | 2.55M | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.67% | 100,341 | 2.22M | Oct 30, 2024 |